| Literature DB >> 31629404 |
Tom Schepens1, Koen Janssens2, Sabine Maes3, Davina Wildemeersch3, Jurryt Vellinga4, Philippe G Jorens5, Vera Saldien3.
Abstract
BACKGROUND: The use of neostigmine after neuromuscular blockade (NMB) has been associated with postoperative respiratory complications. In previous studies, we found lower diaphragmatic activity after neostigmine reversal of NMB, compared to sugammadex. It is still unclear whether the adequate use of neostigmine guarantees normal respiratory muscle function after NMB. In this study, we wanted to assess the effect of commonly used degrees of NMB and their possible reversal strategies on respiratory muscle activity after the return of normal neuromuscular transmission.Entities:
Keywords: Neostigmine; Neuromuscular blockade; Neuromuscular blocking agents; Respiratory outcome; Sugammadex
Mesh:
Substances:
Year: 2019 PMID: 31629404 PMCID: PMC6800991 DOI: 10.1186/s12871-019-0863-y
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Fig. 1Sample of unfiltered EMG data. Top curve (“P3”) shows the pressure/flow signal, indicating inspiratory and expiratory flow. The following 5 curves show the raw EMG per set of leads for the diaphragm and the intercostal muscles. Bottom 5 show amplitudes of these raw signals. To obtain these data, electrodes are positioned bilaterally on the chest wall, on the mid-axillary and midclavicular lines just below the costal margins. The intercostal electrodes are positioned on the mid-clavicular line as well. Changes in electrical currents are measured in between a pair of electrodes, with a reference electrode positioned on the sternum. Currents flowing from the two right and left sided electrodes were labeled aR Dia and aL Dia, those in between the electrodes on the midclavicular line aF Dia, and those placed laterally aD Dia. The final data combined the signals from left and right
Fig. 2Simplified CONSORT flowchart. Legend: NMB: neuromuscular block
Demographics of included patients
| Group | Patients analysed | Age (y) | BMI | Gender (M/F %) | ASA status (1/2) | Surgical time (m) | Reversal time (m) |
|---|---|---|---|---|---|---|---|
| Shallow/saline | 12 | 54 (42–63) | 26 (23–30) | 50/50 | 4/8 | 162 (108–281) | |
| Shallow/sugammadex | 10 | 51 (41–65) | 27 (24–28) | 27/73 | 3/6 | 168 (137–213) | |
| Moderate/neostigmine | 11 | 56 (49–59) | 25 (21–28) | 40/60 | 2/9 | 178 (106–278) | 17 (11–27) |
| Moderate/sugammadex | 13 | 54 (30–68) | 26 (24–28) | 46/54 | 3/10 | 134 (114–198) | 2 (2–2) |
| Deep/sugammadex | 9 | 55 (41–63) | 24 (21–27) | 33/67 | 2/7 | 208 (177–234) | 2 (2–3) |
Age and BMI are displayed as median with interquartile range
Reversal time is the time from administration of neostigmine or sugammadex to TOF ≥ 90%
Surgical time is the from incision to wound closure
BMI: body mass index; ASA: American Society of Anesthesiologists
EMG values and time per group analyzed
| Group | EMGdi (μV) | EMGintercostal (μV) | Time analysed (min) |
|---|---|---|---|
| Shallow/saline | 3.7 (1.7–7.7) | 2.4 (1.4–4.5) | 3.0 (2.5–9.0) |
| Shallow/sugammadex | 4.5 (2.1–8.0) | 2.2 (1.2–4.7) | 5.5 (3.5–7.0) |
| Moderate/neostigmine | 3.2 (0.9–7.3) | 1.5 (1.1–2.5) | 4.0 (3.0–8.0) |
| Moderate/sugammadex | 2.9 (1.3–5.3) | 2.2 (1.3–4.5) | 7.5 (5.0–10.0) |
| Deep/sugammadex | 4.4 (1.9–7.5) | 1.8 (1.1–3.7) | 4.5 (3.0–10.0) |
Data expressed as median with interquartile ranges
EMGdi = diaphragm electromyographic activity; EMGintercostal = intercostal electromyographic activity; μV = microvolt